文献速递心力衰竭与心肌病

退伍军人健康管理局中转甲状腺素蛋白淀粉样变心肌病的延迟诊断

Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration.
PubMed 文献 · J Am Coll Cardiol · 2025-12-17

本研究基于退伍军人健康管理局2016至2022年数据,回顾性分析2557例心衰合并ATTR-CM患者,发现从首次心衰诊断到ATTR-CM诊断的中位时间为490天,房颤、冠心病或慢性肾脏病史与更长的诊断延迟相关。

要点

  • 心衰诊断至ATTR-CM诊断中位延迟490天,提示临床需提高对该病的警觉。
  • 房颤、冠心病或慢性肾脏病史可延长ATTR-CM的诊断时间。
  • 对存在其他心肌病病因的患者,也应考虑合并ATTR-CM的可能。

核心结论

  • 心衰新发至ATTR-CM诊断存在具有临床意义的延迟,中位时间为490天。

研究设计与样本

  • 回顾性队列研究,使用退伍军人健康管理局2016至2022年数据,纳入2557例心衰合并ATTR-CM患者。

主要发现

  • ATTR-CM诊断时平均年龄81岁,99.5%为男性,56%为白人。
  • 从首次心衰诊断至ATTR-CM诊断的中位时间为490天。
  • 在1882例ATTR-CM诊断前已使用袢利尿剂的患者中,从首次袢利尿剂处方至ATTR-CM诊断的中位时间为835天(Q1-Q3:250-1850)。
  • 不同退伍军人事务部站点间的中位诊断时间范围为169至1070天。
  • 调整后,黑人种族(OR:0.71;95% CI:0.57-0.88)和较大年龄(OR:0.66;95% CI:0.59-0.73)与较短诊断时间相关,而房颤史(OR:1.21;95% CI:1.00-1.45)、冠心病(OR:1.38;95% CI:1.15-1.64)或慢性肾脏病(OR:1.79;95% CI:1.50-2.15)与较长诊断时间相关。

临床怎么用

  • 对心衰患者,尤其合并房颤、冠心病或慢性肾脏病者,应警惕ATTR-CM并及时评估。
  • 心衰诊断后应尽快启动ATTR-CM的筛查评估,以缩短诊断延迟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Timely diagnosis and treatment are critical to reduce morbidity and mortality for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Limited existing data suggest underdiagnosis of ATTR-CM and inequity in predictors of diagnosis patterns. OBJECTIVE: This study sought to describe the time from heart failure (HF) diagnosis to ATTR-CM diagnosis and identify predictors for delayed diagnosis of ATTR-CM. METHODS: This retrospective cohort study used Veterans Health Administration (VHA) data. We identified patients with HF and ATTR-CM diagnosed between 2016 and 2022 using an algorithm based on diagnoses and medications. The primary outcome was the time to diagnosis of ATTR-CM and was defined as the number of days between each patient's first HF diagnosis and their first ATTR-CM diagnosis. We also evaluated the number of days between first HF hospitalization or first loop diuretic prescription and ATTR-CM diagnosis. We used multivariable logistic regression to assess demographic, clinical, and socioeconomic predictors of time to ATTR-CM diagnosis using >6 months as a meaningful delay. RESULTS: A total of 2,557 patients with HF and ATTR-CM were identified. The mean age at the time of ATTR-CM diagnosis was 81 years. Most veterans were male (2,544; 99.5%) and White (1,440; 56%). The median time to diagnosis to ATTR-CM was 490 days. For the 1,882 veterans with a loop diuretic prescription before ATTR-CM diagnosis, the median time between initial loop prescription and ATTR-CM diagnosis was 835 days (Q1-Q3: 250-1850). Across Department of Veterans Affairs sites, the median number of days to diagnosis ranged from 169 to 1,070 days. After adjustment, Black race (OR: 0.71; 95% CI: 0.57-0.88) and older age (OR: 0.66; 95% CI: 0.59-0.73) were associated with a shorter time to diagnosis, whereas a history of atrial fibrillation (OR: 1.21; 95% CI: 1.00-1.45), coronary artery disease (OR: 1.38; 95% CI: 1.15-1.64), or chronic kidney disease (OR: 1.79; 95% CI: 1.50-2.15) was associated with longer time to diagnosis. CONCLUSIONS: There are clinically important delays between incident HF and diagnosis of ATTR-CM. Carrying a diagnosis of atrial fibrillation, coronary artery disease, or chronic kidney disease was associated with a longer delay to diagnosis. These findings uncover an opportunity for clinicians to consider concomitant ATTR-CM in patients with alternate etiologies for their cardiomyopathy, as expediting evaluation for ATTR-CM following HF diagnosis is critical to reduce the morbidity of this progressive condition.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Spencer-Bonilla G, Fan J, Cheng P, et al. Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration. J Am Coll Cardiol. 2025. PMID: 41405528. doi:10.1016/j.jacc.2025.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。